LIPO
Price:
$0.74
Market Cap:
$3.31M
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Industry
Biotechnology
IPO Date
2022-12-19
Stock Exchange
NASDAQ
Ticker
LIPO
According to Lipella Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current ROE is -128.33%. This represents a change of 96.51% compared to the average of -65.31% of the last 4 quarters.
The mean historical ROE of Lipella Pharmaceuticals Inc. over the last ten years is -92.81%. The current -128.33% ROE has changed 38.27% with respect to the historical average. Over the past ten years (40 quarters), LIPO's ROE was at its highest in in the September 2022 quarter at 1.14%. The ROE was at its lowest in in the June 2022 quarter at -221.84%.
Average
-92.81%
Median
-93.28%
Minimum
-261.34%
Maximum
52.26%
Discovering the peaks and valleys of Lipella Pharmaceuticals Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 813.69%
Maximum Annual ROE = 52.26%
Minimum Annual Increase = -127.44%
Minimum Annual ROE = -261.34%
Year | ROE | Change |
---|---|---|
2024 | -261.34% | 77.91% |
2023 | -146.89% | 164.56% |
2022 | -55.52% | -57.63% |
2021 | -131.04% | 813.69% |
2020 | -14.34% | -127.44% |
The current ROE of Lipella Pharmaceuticals Inc. (LIPO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-154.58%
5-year avg
-121.83%
10-year avg
-92.81%
Lipella Pharmaceuticals Inc.’s ROE is greater than Processa Pharmaceuticals, Inc. (-319.58%), greater than Acurx Pharmaceuticals, Inc. (-2.05%), less than Fennec Pharmaceuticals Inc. (589.85%), greater than PaxMedica, Inc. Common Stock (-1367.11%), greater than Sangoma Technologies Corporation (-2.69%), greater than Expion360 Inc. (-461.35%),
Company | ROE | Market cap |
---|---|---|
-319.58% | $5.53M | |
-2.05% | $10.36M | |
589.85% | $241.53M | |
-1367.11% | $12.56K | |
-2.69% | $187.97M | |
-461.35% | $3.44M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lipella Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lipella Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Lipella Pharmaceuticals Inc.'s ROE?
How is the ROE calculated for Lipella Pharmaceuticals Inc. (LIPO)?
What is the highest ROE for Lipella Pharmaceuticals Inc. (LIPO)?
What is the 3-year average ROE for Lipella Pharmaceuticals Inc. (LIPO)?
What is the 5-year average ROE for Lipella Pharmaceuticals Inc. (LIPO)?
How does the current ROE for Lipella Pharmaceuticals Inc. (LIPO) compare to its historical average?